These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 24051942

  • 1. [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
    Cappelli V, Di Sabatino A, Musacchio MC, De Leo V.
    Minerva Ginecol; 2013 Aug; 65(4):425-33. PubMed ID: 24051942
    [Abstract] [Full Text] [Related]

  • 2. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G, Cappelli V, Di Sabatino A, Massaro MG, De Leo V.
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [Abstract] [Full Text] [Related]

  • 3. [Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women].
    Musacchio MC, Cappelli V, Di Sabatino A, Morgante G, De Leo V.
    Minerva Ginecol; 2013 Feb; 65(1):89-97. PubMed ID: 23412023
    [Abstract] [Full Text] [Related]

  • 4. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
    Genazzani AD, Prati A, Marchini F, Petrillo T, Napolitano A, Simoncini T.
    Gynecol Endocrinol; 2019 Dec; 35(12):1088-1093. PubMed ID: 31304823
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
    Zacchè MM, Caputo L, Filippis S, Zacchè G, Dindelli M, Ferrari A.
    Gynecol Endocrinol; 2009 Aug; 25(8):508-13. PubMed ID: 19551544
    [Abstract] [Full Text] [Related]

  • 7. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
    Fruzzetti F, Perini D, Russo M, Bucci F, Gadducci A.
    Gynecol Endocrinol; 2017 Jan; 33(1):39-42. PubMed ID: 27808588
    [Abstract] [Full Text] [Related]

  • 8. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
    Singh S, Akhtar N, Ahmad J.
    Diabetes Metab Syndr; 2012 Jan; 6(4):207-11. PubMed ID: 23199540
    [Abstract] [Full Text] [Related]

  • 9. Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action.
    De Cicco S, Immediata V, Romualdi D, Policola C, Tropea A, Di Florio C, Tagliaferri V, Scarinci E, Della Casa S, Lanzone A, Apa R.
    Gynecol Endocrinol; 2017 Sep; 33(9):698-701. PubMed ID: 28434274
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
    Zhao H, Xing C, Zhang J, He B.
    Reprod Health; 2021 Aug 18; 18(1):171. PubMed ID: 34407851
    [Abstract] [Full Text] [Related]

  • 12. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul 18; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 13. Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients.
    Stracquadanio M, Ciotta L, Palumbo MA.
    Gynecol Endocrinol; 2018 Jun 18; 34(6):495-501. PubMed ID: 29265900
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E, Jasonni VM.
    Gynecol Endocrinol; 2007 Mar 18; 23(3):146-52. PubMed ID: 17454168
    [Abstract] [Full Text] [Related]

  • 18. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C, Cardoza L, Coutiño B, Hidalgo R, Arteaga-Troncoso G, Parra A.
    J Endocrinol; 2005 Jan 18; 184(1):233-9. PubMed ID: 15642799
    [Abstract] [Full Text] [Related]

  • 19. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?
    Onalan G, Goktolga U, Ceyhan T, Bagis T, Onalan R, Pabuçcu R.
    Eur J Obstet Gynecol Reprod Biol; 2005 Dec 01; 123(2):204-11. PubMed ID: 16316811
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.